Clinical Evaluation of the Human Tyrosinase Inhibitor Thiamidol (isobutylamido thiazolyl resorcinol) in Prevention of UVB-induced Hyperpigmentation

Clinical Evaluation of the Human Tyrosinase Inhibitor Thiamidol (isobutylamido thiazolyl resorcinol) in Prevention of UVB-induced Hyperpigmentation Vasanop Vachiramon, Chaninan Kositkuljorn, Kanchana Leerunyakul, Kumutnart Chanprapaph Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Background: Thiamidol (isobutylamido thiazolyl resorcinol) has been identified as a potent human tyrosinase inhibitor. A formulation containing Thiamidol has recently shown promising efficacy for the treatment of some hyperpigmentation conditions. Objectives: This study aimed to evaluate the efficacy and safety of a Thiamidol-based formulation in the prevention of ultraviolet (UV)-induced hyperpigmentation. Materials and Methods: We performed a randomized, single-blinded, pilot study in healthy participants, N=30. One arm was randomly assigned to receive a Thiamidol-based formulation for three weeks. Three hyperpigmented spots were induced by UVB irradiation on both arms after 3 weeks of ITR application. Outcome evaluations included measuring mean lightness index (*L) obtained by colorimeter, hyperpigmentation scores by visual analog scale (VAS), and adverse effects. Results: Both experimental sides showed no significant difference in terms of skin lightening after Thiamidol application. However, the Thiamidol-treated sides showed a statistically significant lower mean lightness index compared to control after an induction with UVB. In addition, the Thiamidol-treated sides had an earlier improvement and resumed normal skin color after 3 weeks post-UVB induction. A clinical evaluation by a blinded non-treating physician and subjects was more favorable on the Thiamidol-treated side than the control side (P < .05). No significant side effect was noted. Conclusions: Thiamidol is an effective agent in the prevention of pigmentary change from UVB irradiation and may serve as a promising agent for preventing other hyperpigmentation conditions.

Authors

Publication Details

Journal
SKIN The Journal of Cutaneous Medicine
Published
2025-03-17
DOI
https://doi.org/10.25251/skin.10.supp.545
Primary Topic
melanin and skin pigmentation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical Evaluation of the Human Tyrosinase Inhibitor Thiamidol (isobutylamido thiazolyl resorcinol) in Prevention of UVB-induced Hyperpigmentation

Kanchana Leerunyakul, Vasanop Vachiramon, Chaninan Kositkuljorn, Kumutnart Chanprapaph
SKIN The Journal of Cutaneous Medicine
melanin and skin pigmentation
article

Clinical Evaluation of the Human Tyrosinase Inhibitor Thiamidol (isobutylamido thiazolyl resorcinol) in Prevention of UVB-induced Hyperpigmentation

Kanchana Leerunyakul, Vasanop Vachiramon, Chaninan Kositkuljorn, Kumutnart Chanprapaph
article en

Abstract

Clinical Evaluation of the Human Tyrosinase Inhibitor Thiamidol (isobutylamido thiazolyl resorcinol) in Prevention of UVB-induced Hyperpigmentation Vasanop Vachiramon, Chaninan Kositkuljorn, Kanchana Leerunyakul, Kumutnart Chanprapaph Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Background: Thiamidol (isobutylamido thiazolyl resorcinol) has been identified as a potent human tyrosinase inhibitor. A formulation containing Thiamidol has recently shown promising efficacy for the treatment of some hyperpigmentation conditions. Objectives: This study aimed to evaluate the efficacy and safety of a Thiamidol-based formulation in the prevention of ultraviolet (UV)-induced hyperpigmentation. Materials and Methods: We performed a randomized, single-blinded, pilot study in healthy participants, N=30. One arm was randomly assigned to receive a Thiamidol-based formulation for three weeks. Three hyperpigmented spots were induced by UVB irradiation on both arms after 3 weeks of ITR application. Outcome evaluations included measuring mean lightness index (*L) obtained by colorimeter, hyperpigmentation scores by visual analog scale (VAS), and adverse effects. Results: Both experimental sides showed no significant difference in terms of skin lightening after Thiamidol application. However, the Thiamidol-treated sides showed a statistically significant lower mean lightness index compared to control after an induction with UVB. In addition, the Thiamidol-treated sides had an earlier improvement and resumed normal skin color after 3 weeks post-UVB induction. A clinical evaluation by a blinded non-treating physician and subjects was more favorable on the Thiamidol-treated side than the control side (P < .05). No significant side effect was noted. Conclusions: Thiamidol is an effective agent in the prevention of pigmentary change from UVB irradiation and may serve as a promising agent for preventing other hyperpigmentation conditions.

SKIN The Journal of Cutaneous MedicineVol. 9(2)
Openalex Percentile: Top 95%
melanin and skin pigmentation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.